0001104659-24-031470.txt : 20240306 0001104659-24-031470.hdr.sgml : 20240306 20240306160735 ACCESSION NUMBER: 0001104659-24-031470 CONFORMED SUBMISSION TYPE: 8-K/A PUBLIC DOCUMENT COUNT: 16 CONFORMED PERIOD OF REPORT: 20240229 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20240306 DATE AS OF CHANGE: 20240306 FILER: COMPANY DATA: COMPANY CONFORMED NAME: FENNEC PHARMACEUTICALS INC. CENTRAL INDEX KEY: 0001211583 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] ORGANIZATION NAME: 03 Life Sciences IRS NUMBER: 000000000 STATE OF INCORPORATION: A1 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K/A SEC ACT: 1934 Act SEC FILE NUMBER: 001-32295 FILM NUMBER: 24725901 BUSINESS ADDRESS: STREET 1: PO BOX 13628 STREET 2: 68 TW ALEXANDER DRIVE CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 BUSINESS PHONE: (919) 636-4530 MAIL ADDRESS: STREET 1: PO BOX 13628 STREET 2: 68 TW ALEXANDER DRIVE CITY: RESEARCH TRIANGLE PARK STATE: NC ZIP: 27709 FORMER COMPANY: FORMER CONFORMED NAME: FENNEC PHARMACEUTICALS, INC. DATE OF NAME CHANGE: 20140903 FORMER COMPANY: FORMER CONFORMED NAME: ADHEREX TECHNOLOGIES INC DATE OF NAME CHANGE: 20021223 8-K/A 1 tm248156d1_8ka.htm FORM 8-K/A

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 8-K/A

(Amendment No. 1)

Current Report

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): February 29, 2024

FENNEC PHARMACEUTICALS INC.

(Exact name of registrant as specified in its charter)

001-32295

(Commission File Number)

British Columbia, Canada

20-0442384

(State or other jurisdiction of

incorporation)

(I.R.S. Employer Identification
No.)

PO Box 13628, 68 TW Alexander Drive,

Research Triangle Park, NC

27709

(Address of principal executive offices)

(Zip Code)

Registrant’s telephone number, including area code: (919) 636-4530

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

¨

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

¨

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

¨

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

¨

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	Trading symbol(s)	Name of each exchange on which registered
Common shares, no par value	FENC	Nasdaq Capital Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ¨

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨

Background.

This Amendment No. 1 to the Current Report on Form 8-K/A hereby amends and restates the Current Report on Form 8-K as filed with the Securities and Exchange Commission on February 29, 2024 to properly disclose the results of operations and financial condition of Fennec Pharmaceuticals Inc. (“Fennec” or the “Company”) under Item 2.02.

Item 2.02

Results of Operations and Financial Condition.

On February 29, 2024, Fennec issued a press release announcing financial results for the fourth quarter and full-year ended December 31, 2023. A copy of the Press Release is attached hereto as Exhibit 99.1 and is hereby incorporated by reference in this Item 2.02. The press release did not include certain financial statements, related footnotes and certain other financial information that will be filed with the Securities and Exchange Commission as part of the Company’s Annual Report on Form 10-K.

The information and exhibit contained in this Item 2.02 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, except as shall be expressly set forth by specific reference in such filing.

Item 9.01

Financial Statements and Exhibits.

(d)

Exhibits.

Exhibit No.	Description

99.1	Press Release dated February 29, 2024

104	Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: March 6, 2024	FENNEC PHARMACEUTICALS INC.

	By:	/s/ Rostislav Raykov
		Rostislav Raykov
		Chief Executive Officer

EX-99.1 2 tm248156d1_ex99-1.htm EXHIBIT 99.1

Exhibit 99.1

Fennec Pharmaceuticals Reports Preliminary Unaudited Net Revenue for Fourth Quarter and Full-Year 2023 Results

~ Fourth Quarter 2023 Net Revenues of Approximately $9.2 to $9.7 Million ~

~ Company Expects to Report 2023 Fourth Quarter and Audited Full-Year Results on or about March 26, 2024 ~

RESEARCH TRIANGLE PARK, N.C., February 29, 2024 – Fennec Pharmaceuticals Inc. (NASDAQ: FENC; TSX: FRX), a commercial stage specialty pharmaceutical company, today announced preliminary unaudited fourth quarter and full-year 2023 net revenues.

The information in this press release is based upon preliminary unaudited information and management estimates for the fourth quarter 2023 and is subject to the completion of Fennec’s financial closing procedures and year end audit.

Preliminary Unaudited 2023 Fourth Quarter Revenue and Year End Performance:

•

Fourth quarter 2023 net revenues are expected to be approximately $9.2 to $9.7 million, which represents approximately a 41-49% increase over the third quarter of 2023.

•

Full-year 2023 net revenues are expected to be approximately $20.7 to $21.2 million.

Fennec expects to report its 2023 fourth quarter and audited full-year year results of operations on or about March 26, 2024.

PEDMARK^® (sodium thiosulfate injection)

PEDMARK^® is the first and only U.S. Food and Drug Administration (FDA) approved therapy indicated to reduce the risk of ototoxicity associated with cisplatin treatment in pediatric patients with localized, non-metastatic, solid tumors. It is a unique formulation of sodium thiosulfate in single-dose, ready-to-use vials for intravenous use in pediatric patients. PEDMARK is also the only therapeutic agent with proven efficacy and safety data with an established dosing paradigm, across two open-label, randomized Phase 3 clinical studies, the Clinical Oncology Group (COG) Protocol ACCL0431 and SIOPEL 6.

In the U.S. and Europe, it is estimated that, annually, more than 10,000 children may receive platinum-based chemotherapy. The incidence of ototoxicity depends upon the dose and duration of chemotherapy, and many of these children require lifelong hearing aids. There is currently no established preventive agent for this hearing loss and only expensive, technically difficult, and sub-optimal cochlear (inner ear) implants have been shown to provide some benefit. Infants and young children that suffer ototoxicity at critical stages of development lack speech language development and literacy, and older children and adolescents lack social-emotional development and educational achievement.

PEDMARK has been studied by co-operative groups in two Phase 3 clinical studies of survival and reduction of ototoxicity, COG ACCL0431 and SIOPEL 6. Both studies have been completed. The COG ACCL0431 protocol enrolled childhood cancers typically treated with intensive cisplatin therapy for localized and disseminated disease, including newly diagnosed hepatoblastoma, germ cell tumor, osteosarcoma, neuroblastoma, medulloblastoma, and other solid tumors. SIOPEL 6 enrolled only hepatoblastoma patients with localized tumors.

About Fennec Pharmaceuticals

Fennec Pharmaceuticals Inc. is a specialty pharmaceutical company focused on the development and commercialization of PEDMARK^® and Pedmarqsi^TM to reduce the risk of platinum-induced ototoxicity in pediatric patients. Further, PEDMARK received FDA approval in September 2022 and European Commission Marketing Authorization in June 2023 for Pedmarqsi. PEDMARK has received Orphan Drug Exclusivity in the U.S. for seven years of market protection and Pedmarqsi has received Pediatric Use Marketing Authorization in Europe which includes eight years plus two years of data and market protection. Fennec has a license agreement with Oregon Health and Science University (OHSU) for exclusive worldwide license rights to intellectual property directed to sodium thiosulfate and its use for chemoprotection, including the reduction of risk of ototoxicity induced by platinum chemotherapy, in humans. For more information, please visit www.fennecpharma.com.

Forward Looking Statements

Except for historical information described in this press release, all other statements are forward-looking. Words such as “believe,” “anticipate,” “plan,” “expect,” “estimate,” “intend,” “may,” “will,” or the negative of those terms, and similar expressions, are intended to identify forward-looking statements. These forward-looking statements include statements about our business strategy, timeline, and other goals, plans and prospects, including our commercialization plans respecting PEDMARK^®, the market opportunity for and market impact of PEDMARK^®, its potential impact on patients and anticipated benefits associated with its use, and potential access to further funding after the date of this release. Forward-looking statements are subject to certain risks and uncertainties inherent in the Company’s business that could cause actual results to vary, including the risks and uncertainties that regulatory and guideline developments may change, scientific data and/or manufacturing capabilities may not be sufficient to meet regulatory standards or receipt of required regulatory clearances or approvals, clinical results may not be replicated in actual patient settings, unforeseen global instability, including political instability, or instability from an outbreak of pandemic or contagious disease, such as the novel coronavirus (COVID-19), or surrounding the duration and severity of an outbreak, protection offered by the Company’s patents and patent applications may be challenged, invalidated or circumvented by its competitors, the available market for the Company’s products will not be as large as expected, the Company’s products will not be able to penetrate one or more targeted markets, revenues will not be sufficient to fund further development and clinical studies, our ability to obtain necessary capital when needed on acceptable terms or at all, the Company may not meet its future capital requirements in different countries and municipalities, and other risks detailed from time to time in the Company’s filings with the Securities and Exchange Commission including its Annual Report on Form 10-K for the year ended December 31, 2022. Fennec disclaims any obligation to update these forward-looking statements except as required by law.

For a more detailed discussion of related risk factors, please refer to our public filings available at www.sec.gov and www.sedar.com.

For further information, please contact:

Investors:

Robert Andrade

Chief Financial Officer

Fennec Pharmaceuticals Inc.

(919) 246-5299

Media:

Elixir Health Public Relations

Lindsay Rocco

(862) 596-1304

lrocco@elixirhealthpr.com

EX-101.SCH 3 fencf-20240229.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000001 - Document - Cover link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 fencf-20240229_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Document Type Amendment Flag Amendment Description Document Registration Statement Document Annual Report Document Quarterly Report Document Transition Report Document Shell Company Report Document Shell Company Event Date Document Period Start Date Document Period End Date Document Fiscal Period Focus Document Fiscal Year Focus Current Fiscal Year End Date Entity File Number Entity Registrant Name Entity Central Index Key Entity Primary SIC Number Entity Tax Identification Number Entity Incorporation, State or Country Code Entity Address, Address Line One Entity Address, Address Line Two Entity Address, Address Line Three Entity Address, City or Town Entity Address, State or Province Entity Address, Country Entity Address, Postal Zip Code Country Region City Area Code Local Phone Number Extension Written Communications Soliciting Material Pre-commencement Tender Offer Pre-commencement Issuer Tender Offer Title of 12(b) Security No Trading Symbol Flag Trading Symbol Security Exchange Name Title of 12(g) Security Security Reporting Obligation Annual Information Form Audited Annual Financial Statements Entity Well-known Seasoned Issuer Entity Voluntary Filers Entity Current Reporting Status Entity Interactive Data Current Entity Filer Category Entity Small Business Entity Emerging Growth Company Elected Not To Use the Extended Transition Period Document Accounting Standard Other Reporting Standard Item Number Entity Shell Company Entity Public Float Entity Bankruptcy Proceedings, Reporting Current Entity Common Stock, Shares Outstanding Documents Incorporated by Reference [Text Block] EX-101.PRE 5 fencf-20240229_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 tm247601d1_ex99-1img01.jpg GRAPHIC begin 644 tm247601d1_ex99-1img01.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT

Cover	Feb. 29, 2024
Cover [Abstract]
Document Type	8-K/A
Amendment Flag	false
Document Period End Date	Feb. 29, 2024
Entity File Number	001-32295
Entity Registrant Name	FENNEC PHARMACEUTICALS INC.
Entity Central Index Key	0001211583
Entity Tax Identification Number	20-0442384
Entity Incorporation, State or Country Code	A1
Entity Address, Address Line One	PO Box 13628
Entity Address, Address Line Two	68 TW Alexander Drive
Entity Address, City or Town	Research Triangle Park
Entity Address, State or Province	NC
Entity Address, Postal Zip Code	27709
City Area Code	919
Local Phone Number	636-4530
Written Communications	false
Soliciting Material	false
Pre-commencement Tender Offer	false
Pre-commencement Issuer Tender Offer	false
Title of 12(b) Security	Common shares, no par value
Trading Symbol	FENC
Security Exchange Name	NASDAQ
Entity Emerging Growth Company	false

EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 13 FilingSummary.xml IDEA: XBRL DOCUMENT 3.24.0.1 html 1 23 1 false 0 0 false 3 false false R1.htm 00000001 - Document - Cover Sheet http://adherex.com/role/Cover Cover Cover 1 false false All Reports Book All Reports fencf-20240229.xsd fencf-20240229_lab.xml fencf-20240229_pre.xml tm248156d1_8ka.htm http://xbrl.sec.gov/dei/2023 true false JSON 15 MetaLinks.json IDEA: XBRL DOCUMENT { "version": "2.2", "instance": { "tm248156d1_8ka.htm": { "nsprefix": "fencf", "nsuri": "http://adherex.com/20240229", "dts": { "schema": { "local": [ "fencf-20240229.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/2006/ref-2006-02-27.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/2020/extensible-enumerations-2.0.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-roles-2023.xsd", "https://xbrl.fasb.org/srt/2023/elts/srt-types-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-gaap-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-roles-2023.xsd", "https://xbrl.fasb.org/us-gaap/2023/elts/us-types-2023.xsd", "https://xbrl.sec.gov/country/2023/country-2023.xsd", "https://xbrl.sec.gov/dei/2023/dei-2023.xsd" ] }, "labelLink": { "local": [ "fencf-20240229_lab.xml" ] }, "presentationLink": { "local": [ "fencf-20240229_pre.xml" ] }, "inline": { "local": [ "tm248156d1_8ka.htm" ] } }, "keyStandard": 23, "keyCustom": 0, "axisStandard": 0, "axisCustom": 0, "memberStandard": 0, "memberCustom": 0, "hidden": { "total": 2, "http://xbrl.sec.gov/dei/2023": 2 }, "contextCount": 1, "entityCount": 1, "segmentCount": 0, "elementCount": 59, "unitCount": 3, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2023": 23 }, "report": { "R1": { "role": "http://adherex.com/role/Cover", "longName": "00000001 - Document - Cover", "shortName": "Cover", "isDefault": "true", "groupType": "document", "subGroupType": "", "menuCat": "Cover", "order": "1", "firstAnchor": { "contextRef": "AsOf2024-02-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm248156d1_8ka.htm", "first": true, "unique": true }, "uniqueAnchor": { "contextRef": "AsOf2024-02-29", "name": "dei:DocumentType", "unitRef": null, "xsiNil": "false", "lang": "en-US", "decimals": null, "ancestors": [ "span", "b", "p", "body", "html" ], "reportCount": 1, "baseRef": "tm248156d1_8ka.htm", "first": true, "unique": true } } }, "tag": { "dei_AmendmentDescription": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentDescription", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Description", "documentation": "Description of changes contained within amended document." } } }, "auth_ref": [] }, "dei_AmendmentFlag": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AmendmentFlag", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Amendment Flag", "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission." } } }, "auth_ref": [] }, "dei_AnnualInformationForm": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AnnualInformationForm", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Annual Information Form", "documentation": "Boolean flag with value true on a form if it is an annual report containing an annual information form." } } }, "auth_ref": [ "r14" ] }, "dei_AuditedAnnualFinancialStatements": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "AuditedAnnualFinancialStatements", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Audited Annual Financial Statements", "documentation": "Boolean flag with value true on a form if it is an annual report containing audited financial statements." } } }, "auth_ref": [ "r14" ] }, "dei_CityAreaCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CityAreaCode", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "City Area Code", "documentation": "Area code of city" } } }, "auth_ref": [] }, "dei_CountryRegion": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CountryRegion", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Country Region", "documentation": "Region code of country" } } }, "auth_ref": [] }, "dei_CoverAbstract": { "xbrltype": "stringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CoverAbstract", "lang": { "en-us": { "role": { "label": "Cover [Abstract]", "documentation": "Cover page." } } }, "auth_ref": [] }, "dei_CurrentFiscalYearEndDate": { "xbrltype": "gMonthDayItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "CurrentFiscalYearEndDate", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Current Fiscal Year End Date", "documentation": "End date of current fiscal year in the format --MM-DD." } } }, "auth_ref": [] }, "dei_DocumentAccountingStandard": { "xbrltype": "accountingStandardItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAccountingStandard", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Accounting Standard", "documentation": "The basis of accounting the registrant has used to prepare the financial statements included in this filing This can either be 'U.S. GAAP', 'International Financial Reporting Standards', or 'Other'." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentAnnualReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentAnnualReport", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Annual Report", "documentation": "Boolean flag that is true only for a form used as an annual report." } } }, "auth_ref": [ "r11", "r13", "r14" ] }, "dei_DocumentFiscalPeriodFocus": { "xbrltype": "fiscalPeriodItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalPeriodFocus", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Period Focus", "documentation": "Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY." } } }, "auth_ref": [] }, "dei_DocumentFiscalYearFocus": { "xbrltype": "gYearItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentFiscalYearFocus", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Fiscal Year Focus", "documentation": "This is focus fiscal year of the document report in YYYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006." } } }, "auth_ref": [] }, "dei_DocumentPeriodEndDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodEndDate", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period End Date", "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD." } } }, "auth_ref": [] }, "dei_DocumentPeriodStartDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentPeriodStartDate", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Period Start Date", "documentation": "The start date of the period covered in the document, in YYYY-MM-DD format." } } }, "auth_ref": [] }, "dei_DocumentQuarterlyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentQuarterlyReport", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Quarterly Report", "documentation": "Boolean flag that is true only for a form used as an quarterly report." } } }, "auth_ref": [ "r12" ] }, "dei_DocumentRegistrationStatement": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentRegistrationStatement", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Registration Statement", "documentation": "Boolean flag that is true only for a form used as a registration statement." } } }, "auth_ref": [ "r0" ] }, "dei_DocumentShellCompanyEventDate": { "xbrltype": "dateItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyEventDate", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Event Date", "documentation": "Date of event requiring a shell company report." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentShellCompanyReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentShellCompanyReport", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Shell Company Report", "documentation": "Boolean flag that is true for a Shell Company Report pursuant to section 13 or 15(d) of the Exchange Act." } } }, "auth_ref": [ "r13" ] }, "dei_DocumentTransitionReport": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentTransitionReport", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Transition Report", "documentation": "Boolean flag that is true only for a form used as a transition report." } } }, "auth_ref": [ "r15" ] }, "dei_DocumentType": { "xbrltype": "submissionTypeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentType", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Document Type", "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'." } } }, "auth_ref": [] }, "dei_DocumentsIncorporatedByReferenceTextBlock": { "xbrltype": "textBlockItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "DocumentsIncorporatedByReferenceTextBlock", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Documents Incorporated by Reference [Text Block]", "documentation": "Documents incorporated by reference." } } }, "auth_ref": [ "r3" ] }, "dei_EntityAddressAddressLine1": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine1", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line One", "documentation": "Address Line 1 such as Attn, Building Name, Street Name" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine2": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine2", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Two", "documentation": "Address Line 2 such as Street or Suite number" } } }, "auth_ref": [] }, "dei_EntityAddressAddressLine3": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressAddressLine3", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Address Line Three", "documentation": "Address Line 3 such as an Office Park" } } }, "auth_ref": [] }, "dei_EntityAddressCityOrTown": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCityOrTown", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, City or Town", "documentation": "Name of the City or Town" } } }, "auth_ref": [] }, "dei_EntityAddressCountry": { "xbrltype": "countryCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressCountry", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Country", "documentation": "ISO 3166-1 alpha-2 country code." } } }, "auth_ref": [] }, "dei_EntityAddressPostalZipCode": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressPostalZipCode", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, Postal Zip Code", "documentation": "Code for the postal or zip code" } } }, "auth_ref": [] }, "dei_EntityAddressStateOrProvince": { "xbrltype": "stateOrProvinceItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityAddressStateOrProvince", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Address, State or Province", "documentation": "Name of the state or province." } } }, "auth_ref": [] }, "dei_EntityBankruptcyProceedingsReportingCurrent": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityBankruptcyProceedingsReportingCurrent", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Bankruptcy Proceedings, Reporting Current", "documentation": "For registrants involved in bankruptcy proceedings during the preceding five years, the value Yes indicates that the registrant has filed all documents and reports required to be filed by Section 12, 13 or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court; the value No indicates the registrant has not. Registrants not involved in bankruptcy proceedings during the preceding five years should not report this element." } } }, "auth_ref": [ "r6" ] }, "dei_EntityCentralIndexKey": { "xbrltype": "centralIndexKeyItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCentralIndexKey", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Central Index Key", "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK." } } }, "auth_ref": [ "r2" ] }, "dei_EntityCommonStockSharesOutstanding": { "xbrltype": "sharesItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCommonStockSharesOutstanding", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Common Stock, Shares Outstanding", "documentation": "Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument." } } }, "auth_ref": [] }, "dei_EntityCurrentReportingStatus": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityCurrentReportingStatus", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Current Reporting Status", "documentation": "Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [] }, "dei_EntityEmergingGrowthCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityEmergingGrowthCompany", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Emerging Growth Company", "documentation": "Indicate if registrant meets the emerging growth company criteria." } } }, "auth_ref": [ "r2" ] }, "dei_EntityExTransitionPeriod": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityExTransitionPeriod", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Elected Not To Use the Extended Transition Period", "documentation": "Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards." } } }, "auth_ref": [ "r19" ] }, "dei_EntityFileNumber": { "xbrltype": "fileNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFileNumber", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity File Number", "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen." } } }, "auth_ref": [] }, "dei_EntityFilerCategory": { "xbrltype": "filerCategoryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityFilerCategory", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Filer Category", "documentation": "Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure." } } }, "auth_ref": [ "r2" ] }, "dei_EntityIncorporationStateCountryCode": { "xbrltype": "edgarStateCountryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityIncorporationStateCountryCode", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Incorporation, State or Country Code", "documentation": "Two-character EDGAR code representing the state or country of incorporation." } } }, "auth_ref": [] }, "dei_EntityInteractiveDataCurrent": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityInteractiveDataCurrent", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Interactive Data Current", "documentation": "Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files)." } } }, "auth_ref": [ "r16" ] }, "dei_EntityPrimarySicNumber": { "xbrltype": "sicNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPrimarySicNumber", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Primary SIC Number", "documentation": "Primary Standard Industrial Classification (SIC) Number for the Entity." } } }, "auth_ref": [ "r14" ] }, "dei_EntityPublicFloat": { "xbrltype": "monetaryItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityPublicFloat", "crdr": "credit", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Public Float", "documentation": "The aggregate market value of the voting and non-voting common equity held by non-affiliates computed by reference to the price at which the common equity was last sold, or the average bid and asked price of such common equity, as of the last business day of the registrant's most recently completed second fiscal quarter." } } }, "auth_ref": [] }, "dei_EntityRegistrantName": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityRegistrantName", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Registrant Name", "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC." } } }, "auth_ref": [ "r2" ] }, "dei_EntityShellCompany": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityShellCompany", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Shell Company", "documentation": "Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act." } } }, "auth_ref": [ "r2" ] }, "dei_EntitySmallBusiness": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntitySmallBusiness", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Small Business", "documentation": "Indicates that the company is a Smaller Reporting Company (SRC)." } } }, "auth_ref": [ "r2" ] }, "dei_EntityTaxIdentificationNumber": { "xbrltype": "employerIdItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityTaxIdentificationNumber", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Tax Identification Number", "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS." } } }, "auth_ref": [ "r2" ] }, "dei_EntityVoluntaryFilers": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityVoluntaryFilers", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Voluntary Filers", "documentation": "Indicate 'Yes' or 'No' if the registrant is not required to file reports pursuant to Section 13 or Section 15(d) of the Act." } } }, "auth_ref": [] }, "dei_EntityWellKnownSeasonedIssuer": { "xbrltype": "yesNoItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "EntityWellKnownSeasonedIssuer", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Entity Well-known Seasoned Issuer", "documentation": "Indicate 'Yes' or 'No' if the registrant is a well-known seasoned issuer, as defined in Rule 405 of the Securities Act. Is used on Form Type: 10-K, 10-Q, 8-K, 20-F, 6-K, 10-K/A, 10-Q/A, 20-F/A, 6-K/A, N-CSR, N-Q, N-1A." } } }, "auth_ref": [ "r17" ] }, "dei_Extension": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Extension", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Extension", "documentation": "Extension number for local phone number." } } }, "auth_ref": [] }, "dei_LocalPhoneNumber": { "xbrltype": "normalizedStringItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "LocalPhoneNumber", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Local Phone Number", "documentation": "Local phone number for entity." } } }, "auth_ref": [] }, "dei_NoTradingSymbolFlag": { "xbrltype": "trueItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "NoTradingSymbolFlag", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "No Trading Symbol Flag", "documentation": "Boolean flag that is true only for a security having no trading symbol." } } }, "auth_ref": [] }, "dei_OtherReportingStandardItemNumber": { "xbrltype": "otherReportingStandardItemNumberItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "OtherReportingStandardItemNumber", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Other Reporting Standard Item Number", "documentation": "\"Item 17\" or \"Item 18\" specified when the basis of accounting is neither US GAAP nor IFRS." } } }, "auth_ref": [ "r13" ] }, "dei_PreCommencementIssuerTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementIssuerTenderOffer", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Issuer Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act." } } }, "auth_ref": [ "r7" ] }, "dei_PreCommencementTenderOffer": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "PreCommencementTenderOffer", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Pre-commencement Tender Offer", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act." } } }, "auth_ref": [ "r8" ] }, "dei_Security12bTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12bTitle", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(b) Security", "documentation": "Title of a 12(b) registered security." } } }, "auth_ref": [ "r1" ] }, "dei_Security12gTitle": { "xbrltype": "securityTitleItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "Security12gTitle", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Title of 12(g) Security", "documentation": "Title of a 12(g) registered security." } } }, "auth_ref": [ "r5" ] }, "dei_SecurityExchangeName": { "xbrltype": "edgarExchangeCodeItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityExchangeName", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Exchange Name", "documentation": "Name of the Exchange on which a security is registered." } } }, "auth_ref": [ "r4" ] }, "dei_SecurityReportingObligation": { "xbrltype": "securityReportingObligationItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SecurityReportingObligation", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Security Reporting Obligation", "documentation": "15(d), indicating whether the security has a reporting obligation under that section of the Exchange Act." } } }, "auth_ref": [ "r9" ] }, "dei_SolicitingMaterial": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "SolicitingMaterial", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Soliciting Material", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act." } } }, "auth_ref": [ "r10" ] }, "dei_TradingSymbol": { "xbrltype": "tradingSymbolItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "TradingSymbol", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Trading Symbol", "documentation": "Trading symbol of an instrument as listed on an exchange." } } }, "auth_ref": [] }, "dei_WrittenCommunications": { "xbrltype": "booleanItemType", "nsuri": "http://xbrl.sec.gov/dei/2023", "localname": "WrittenCommunications", "presentation": [ "http://adherex.com/role/Cover" ], "lang": { "en-us": { "role": { "label": "Written Communications", "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act." } } }, "auth_ref": [ "r18" ] } } } }, "std_ref": { "r0": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12" }, "r1": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b" }, "r2": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-2" }, "r3": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "b-23" }, "r4": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "d1-1" }, "r5": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12", "Subsection": "g" }, "r6": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "12, 13, 15d" }, "r7": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "13e", "Subsection": "4c" }, "r8": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "14d", "Subsection": "2b" }, "r9": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Number": "240", "Section": "15", "Subsection": "d" }, "r10": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Exchange Act", "Section": "14a", "Number": "240", "Subsection": "12" }, "r11": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-K", "Number": "249", "Section": "310" }, "r12": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 10-Q", "Number": "240", "Section": "308", "Subsection": "a" }, "r13": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 20-F", "Number": "249", "Section": "220", "Subsection": "f" }, "r14": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Form 40-F", "Number": "249", "Section": "240", "Subsection": "f" }, "r15": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Forms 10-K, 10-Q, 20-F", "Number": "240", "Section": "13", "Subsection": "a-1" }, "r16": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Regulation S-T", "Number": "232", "Section": "405" }, "r17": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "405" }, "r18": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "230", "Section": "425" }, "r19": { "role": "http://www.xbrl.org/2003/role/presentationRef", "Publisher": "SEC", "Name": "Securities Act", "Number": "7A", "Section": "B", "Subsection": "2" } } } ZIP 16 0001104659-24-031470-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001104659-24-031470-xbrl.zip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end XML 17 tm248156d1_8ka_htm.xml IDEA: XBRL DOCUMENT 0001211583 2024-02-29 2024-02-29 iso4217:USD shares iso4217:USD shares false 0001211583 8-K/A 2024-02-29 FENNEC PHARMACEUTICALS INC. 001-32295 A1 20-0442384 PO Box 13628 68 TW Alexander Drive Research Triangle Park NC 27709 919 636-4530 false false false false Common shares, no par value FENC NASDAQ false